Those on a 10 mg dose lost an average of 19.5%, and those on a 15 mg dose lost 20.9% after a 72-week period
It only takes a few minutes and helps our clinical team understand your goals and health history so they can create a customized treatment plan
As of September 2025, Novo Nordisk has filed 140 lawsuits and issued 1K cease-and-desist letters against GLP-1 compounders
Both Drucker and Nauck expect this trend will continue, with the drugs eventually used to help control cardiovascular risk in people without either diabetes or obesity
Long-term low B12 can drive elevated homocysteine and contribute to megaloblastic or pernicious anemia
Optimizing your tirzepatide investment Whether you use Afterpay, Klarna, CareCredit, or pay cash, getting the most value from your tirzepatide investment goes beyond payment method